Latest Ambrisentan Stories
WESTMINSTER, Colo., May 4, 2011 /PRNewswire/ -- Plato BioPharma, Inc. (PBI) and Gilead Sciences, Inc.
Monthly liver enzyme testing is no longer required SILVER SPRING, Md., March 4, 2011 /PRNewswire-USNewswire/ -- The U.S.
WALTHAM, Mass., June 9 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that while United Therapeutics' Tyvaso and Adcirca--launched in 2009--are each prescribed by more than half of surveyed pulmonologists in the specialized pulmonary arterial hypertension (PAH) center setting, Adcirca is much more widely used than Tyvaso among surveyed non-PAH-center physicians. The new Physician & Payer Forum...
Research team reviews outcomes after 2 years of treatment with ambrisentan.
Can these drugs help with a wider array of diseases? Expert to address conference of experts Being sponsored by the American Physiological Society (APS).
Gilead Sciences, Inc. (Nasdaq:GILD) today announced results of a two-year (104-week), open-label, uncontrolled, extension study (ARIES-E) of Letairis(R) in patients with pulmonary arterial hypertension (PAH) (WHO Group 1).
Actelion has announced that Tracleer, a dual endothelin receptor antagonist, has been approved in the European Union for the treatment of patients with mildly symptomatic pulmonary arterial hypertension.
WASHINGTON (Reuters) - Encysive Pharmaceuticals Inc.'s drug Thelin is "approvable" for treating a rare, often-fatal lung condition, a U.S. Food and Drug Administration (FDA) spokeswoman said on Friday.
- In Roman antiquity, the return of a person who had been banished, or taken prisoner by an enemy, to his old condition and former privileges.
- In international law, that right by virtue of which persons and things taken by an enemy in war are restored to their former status when coming again under the power of the nation to which they belonged.